Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPD | P32754 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222959 | 0.86 | ALDH1A1 (0.63) | ALDH1A1CYP2D6CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL6221006 | 0.84 | POLB (0.61) | ALDH1A1CYP2D6CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL6219696 | 0.84 | POLB (0.56) | ALDH1A1CYP2D6CYP2C19POLBHCAR1 | |
| SCHEMBL6214102 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP2D6CYP2C19POLBHCAR1 | |
| SCHEMBL1703867 | 0.80 | POLB (0.74) | ALDH1A1POLBHCAR1SMN1; SMN2PDE4B | |
| SCHEMBL6219083 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP2D6CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL6219085 | 0.78 | LMNA (0.45) | ALDH1A1CYP2D6CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL9734325 | 0.78 | ALDH1A1 (1.00) | ALDH1A1CYP2D6CYP2C19POLBHCAR1 | |
| Mecloqualone SCHEMBL30726104 | 0.77 | ALDH1A1 (0.73) | ALDH1A1CYP2D6CYP2C19POLBHCAR1 | |
| Mecloqualone SCHEMBL30726100 | 0.77 | ALDH1A1 (0.73) | ALDH1A1CYP2D6CYP2C19POLBHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884310-B1 | Quinazolin-4-one ampa antagonists | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6921764-B2 | Thieno-pyrimidin-4-one AMPA antagonists | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-0900799-B1 | Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones | PFIZER PROD INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6627755-B1 | Neurodegenerative, psychological, and nervous system disorder; drug abuse, alcoholism | PFIZER INC | 2003-09-30 | — | — | US | disclosed |
| EP-0807633-B1 | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones | PFIZER (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6323208-B1 | COMPOUNDS TO TREAT NEURODEGENERATIVE, PSYCHOTROPIC DRUG AND ALCOHOL INDUCED CENTRAL AND INDUCED CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS. | PFIZER INC | 2001-11-27 | — | — | US | disclosed |
| EP-0900799-A1 | Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0884310-A1 | Quinazolin-4-one ampa antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0807633-A2 | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones | PFIZER INC. (US) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | GRIN1, GRIK1, GRIN3A | ALDH1A1 255/4885CYP2D6 1634/4885CYP2C19 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.